siRNA therapy shows long-term potential in lowering LDL-C
New data presented at the European Society of Cardiology (ESC)…
New data presented at the European Society of Cardiology (ESC) Congress 2023, showed Novartis’ Leqvio® (inclisiran) provided an approximate 49 percent reduction in LDL cholesterol beyond six years of clinical observation.